Landscape of the clinical development of China innovative anti-lung cancer drugs by Yuankai Shi

Get full text

Prognostic value of pretreatment smoking status for small cell lung cancer: A meta‐analysis by Liling Huang, Yuankai Shi

Get full text

Development and Validation of a Novel Risk Stratification Model for Cancer-Specific Survival in Diffuse Large B-Cell Lymphoma by Qiaofeng Zhong, Yuankai Shi

Get full text

Cancer Pathogenesis and Therapy: A new journal, a new inspiration by Yuankai Shi, David James Kerr

Get full text

Advances in Drug Resistance Mechanisms and Prognostic Markers of Targeted Therapy in ALK-positive Non-small Cell Lung Cancer by Shasha WANG, Yuankai SHI, Xiaohong HAN

Get full text

Efficacy and Safety of Albumin-bound Paclitaxel 
in Treating Recurrent Advanced Non-small Cell Lung Cancer by Puyuan XING, Junling LI, Yuankai SHI

Get full text

The prognostic significance of tumor spread through air space in stage I lung adenocarcinoma by Liling Huang, Le Tang, Liyuan Dai, Yuankai Shi

Get full text

Immunogenomic correlates of immune-related adverse events for anti–programmed cell death 1 therapy by Lei Zhang, Lei Zhang, Yuankai Shi, Xiaohong Han

Get full text

MUC16: The Novel Target for Tumor Therapy by Ruyun GAO, Ning LOU, Xiaohong HAN, Yuankai SHI

Get full text

Effect of rs2293347 Polymorphism in EGFR on the Clinical Efficacy of Gefitinib 
in Patients with Non-small Cell Lung Cancer by Fei MA, Binghe XU, Dongxin LIN, Tong SUN, Yuankai SHI

Get full text

Antitumor effects of a novel chromosome region maintenance 1 (CRM1) inhibitor on non-small cell lung cancer cells in vitro and in mouse tumor xenografts. by Shuai Wang, Xiaohong Han, Jianfei Wang, Jiarui Yao, Yuankai Shi

Get full text

Response of Lung Adenocarcinoma Harbouring Sensitizing EGFR Mutation
to the Fourth-line Combination Treatment of Pembrolizumab and Anlotinib by Liling HUANG, Yan QIN, Fengyi ZHAO, Shengyu ZHOU, Yuankai SHI

Get full text

Efficacy of Pemetrexed as Second-line Therapy or Beyond in Patients 
with Advanced Non-small Cell Lung Cancer by Junling LI, Jing WANG, Xuezhi HAO, Xiangru ZHANG, Yuankai SHI

Get full text

Clinical Experience of Gefitinib in the Treatment of 32 Lung Adenocarcinoma Patients with Brain Metastases by Jianping XU, Xiaoyan LIU, Sheng YANG, Xiangru ZHANG, Yuankai SHI

Get full text

Efficacy and safety of utidelone for the treatment of patients with locally advanced or metastatic non-small-cell lung cancer who have failed standard second-line treatment: A phas... by Yuankai Shi, Gongyan Chen, Yanqiu Zhao, Jing Zhao, Lin Lin

Get full text

Incidence, survival comparison, and novel prognostic evaluation approaches for stage iii-iv pulmonary large cell neuroendocrine carcinoma and small cell lung cancer by Liling Huang, Yu Feng, Tongji Xie, Haohua Zhu, Le Tang, Yuankai Shi

Get full text

Single-cell and spatial analyses revealed the co-location of cancer stem cells and SPP1+ macrophage in hypoxic region that determines the poor prognosis in hepatocellular carcinoma by Guangyu Fan, Tongji Xie, Lin Li, Le Tang, Xiaohong Han, Yuankai Shi

Get full text

Therapeutic cancer vaccine: phase I clinical tolerance study of Hu-rhEGF-rP64k/Mont in patients with newly diagnosed advanced non-small cell lung cancer by Puyuan Xing, Hongyu Wang, Sheng Yang, Xiaohong Han, Yan Sun, Yuankai Shi

Get full text

The exploration of three different treatment models of osimertinib plus antiangiogenic agents in non‐small cell lung cancer: A real‐world study by Yu Feng, Liling Huang, Haohua Zhu, Le Tang, Xingsheng Hu, Yuankai Shi

Get full text

Treatment Choice for Advanced Non-small Cell Lung Cancer Patients Who Had Gradual Progression After EGFR-TKIs: 32 Cases Report by Lin LIN, Bin WANG, Xuezhi HAO, Puyuan XING, Junling LI, Xiangru ZHANG, Yuankai SHI

Get full text